iNKT cell modulators and methods of using the same
AssigneeLudwig Institute for Cancer Research
InventorsVincenzo Cerundolo, Gurdyal S. Besra, Liam R. Cox
Life of this patent
Estimating the term…
Abstract
Disclosed herein are α-galactosylceramide (α-GalCer) analogs and compositions thereof, methods of activating invariant Natural Killer T (iNKT) cells using said analogs, methods of treating diseases by activating iNKT cells using said analogs, and combination therapy of said analogs.
Claims28
A method of activating a natural killer T (NKT) cell in a human subject with ovarian cancer, the method comprising administering to a subject with ovarian cancer a composition comprising a compound, in an amount effective to activate the NKT cells, wherein the compound has a structure:
- wherein n is 1, 2, or 3;
- or a salt, ester, solvate, or hydrate thereof.
A method of treating a subject suffering from ovarian cancer comprising administering to the subject a composition comprising a compound, or a salt, ester, solvate, or hydrate thereof, in an amount effective to treat the cancer, wherein the compound has a structure:
- wherein n is 1, 2, or 3.
Dependencies are inferred from the claim text.